Please check your internet connection and try again.
# Ezivac Enema
## Overview
Ezivac is a hypertonic phosphate enema solution containing monobasic sodium phosphate and dibasic sodium phosphate. It acts as an osmotic saline laxative, drawing water into the colon to stimulate peristalsis and induce defecation.
## Primary Indications
* Relief of occasional constipation.
* Bowel clearance prior to rectal examinations or endoscopic procedures.
## Adult Dosing
* **Standard dose:** One ready-to-use unit (typically 118 mL volume containing 19g monobasic sodium phosphate and 7g dibasic sodium phosphate) administered rectally as a single dose.
* **Maximum:** Do not exceed one dose in a 24-hour period.
## Pediatric Dosing
* **Children ≥ 12 years:** Use adult dosing.
* **Children 2–11 years:** 59 mL (half-unit) administered rectally.
* **Children < 2 years:** Contraindicated.
* *Note:* Always verify local pharmacy/hospital protocols for pediatric specific volume and administration frequency.
## Dose Adjustments
* **Renal Impairment:** Use with extreme caution. Severe hyperphosphatemia, hypocalcemia, and hypernatremia may occur due to systemic absorption of phosphates if renal clearance is impaired.
* **Hydration:** Ensure adequate oral fluid intake before and after administration to prevent dehydration.
## Contraindications
* Hypersensitivity to any component.
* Known or suspected bowel obstruction, perforation, or megacolon.
* Congestive heart failure or severe renal failure.
* Acute surgical abdomen or inflammatory bowel disease (active).
* Presence of anorectal fissures or hemorrhoids.
## Adverse Effects
* **Common:** Rectal irritation, painful anal fissures, fullness, or cramping.
* **Serious:** Electrolyte imbalances (hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia), dehydration, metabolic acidosis, and cardiac arrhythmias (secondary to electrolyte shifts).
## Key Drug Interactions
* **Diuretics (loop/thiazide):** May increase risk of dehydration and electrolyte abnormalities.
* **Calcium Channel Blockers:** May be affected by acute changes in serum calcium levels.
* **Parathyroid medications:** Phosphate load may interfere with therapeutic management of parathyroid disorders.
* **Other laxatives:** Concurrent use increases risk of dehydration and mucosal damage.
## Monitoring
* Monitor for signs of dehydration (thirst, decreased urine output).
* In patients at risk, monitor electrolytes (phosphate, calcium, sodium, potassium) following administration.
* Assess for rectal bleeding or failure to evacuate stool after administration.
## Clinical Pearls
* Administer the solution at room temperature or slightly warmed (do not overheat).
* Instruct the patient to lie on the left side with knees bent to facilitate flow.
* The effect typically occurs within 2 to 15 minutes.
* Prolonged or frequent use should be avoided to prevent dependency and electrolyte disturbances.
* Stop administration if resistance is felt; force should never be used, as it can cause mucosal injury.
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Always verify current prescribing information, institutional protocols, and patient-specific factors before administration.*
